Announced details
Cartilage diseases (traumatic cartilage defects, osteoarthritis and osteochondritis dissecans)
Redasemtide has been out-licensed to Shionogi & Co.,Ltd. The applicants for the patent are StemRIM Inc. and National University Corporation Osaka University.
Shionogi & Co.,Ltd.: headquarters in Kita-ku, Osaka; Representative Director, Chairman and President, CEO: Teshigaki Isao (手代木 功). National University Corporation Osaka University: other details are Not disclosed.
Application number: 10-2021-7015301. Registration (publication) number: not yet determined. Term of validity: Not disclosed
There will be no impact on full-year results for the fiscal year ending July 2027. The Company will promptly disclose any matters requiring disclosure that arise.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Redasemtide (HMGB1 fragment peptide, development code: S-005151) |
| Counterparty | Shionogi & Co.,Ltd.; National University Corporation Osaka University |
| Counterparty overview | Shionogi & Co.,Ltd.: headquarters in Kita-ku, Osaka; Representative Director, Chairman and President, CEO: Teshigaki Isao (手代木 功). National University Corporation Osaka University: other details are Not disclosed. |
| Relationship with the Company | Redasemtide has been out-licensed to Shionogi & Co.,Ltd. The applicants for the patent are StemRIM Inc. and National University Corporation Osaka University. |
| Applicable area | Cartilage diseases (traumatic cartilage defects, osteoarthritis and osteochondritis dissecans) |
| Registration number and expiry date | Application number: 10-2021-7015301. Registration (publication) number: not yet determined. Term of validity: Not disclosed |
| Impact on Business Performance | There will be no impact on full-year results for the fiscal year ending July 2027. The Company will promptly disclose any matters requiring disclosure that arise. |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The purpose is to expand the indications for redasemtide and secure the possibility of developing a treatment for cartilage diseases in South Korea.